TriageHF Plus
Awaiting development [GID-DG10064] Expected publication date: TBC
Search results
217 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014]
Awaiting development [GID-TA10914] Expected publication date: 01 February 2023
-
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]
Awaiting development [GID-TA10934] Expected publication date: TBC
-
Fordadistrogene movaparvovec for the treatment of Duchenne muscular dystrophy TS ID 10420
Awaiting development [GID-TA11044] Expected publication date: TBC
-
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947
Awaiting development [GID-TA10834] Expected publication date: TBC
-
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Awaiting development [GID-TA11050] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637
Awaiting development [GID-TA11045] Expected publication date: TBC
-
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657
Awaiting development [GID-TA11046] Expected publication date: TBC
-
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Awaiting development [GID-TA11053] Expected publication date: TBC
-
Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762
Awaiting development [GID-TA11047] Expected publication date: TBC
-
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Awaiting development [GID-TA11048] Expected publication date: TBC
-
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Awaiting development [GID-TA11049] Expected publication date: TBC
-
Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605
Awaiting development [GID-TA11051] Expected publication date: TBC
-
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Awaiting development [GID-TA11052] Expected publication date: TBC
-
Empagliflozin for treating chronic kidney disease TS ID 10698
Awaiting development [GID-TA11043] Expected publication date: TBC
-
Daridorexant for treating insomnia disorder [ID3774]
Awaiting development [GID-TA10888] Expected publication date: 16 August 2023
-
Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593
Awaiting development [GID-TA10957] Expected publication date: TBC
-
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]
Awaiting development [GID-TA10723] Expected publication date: TBC
-
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]
Awaiting development [GID-TA10728] Expected publication date: TBC
-
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Awaiting development [GID-TA10747] Expected publication date: TBC
-
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Awaiting development [GID-TA10748] Expected publication date: TBC
-
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Awaiting development [GID-TA10741] Expected publication date: TBC
-
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]
Awaiting development [GID-TA10821] Expected publication date: TBC
-
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Awaiting development [GID-TA10720] Expected publication date: TBC
-
Liposomal bupivacaine for treating postoperative pain [ID3799]
Awaiting development [GID-TA10681] Expected publication date: TBC
-
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)
Awaiting development [GID-TA10306] Expected publication date: TBC
-
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)
Awaiting development [GID-TA10426] Expected publication date: TBC
-
Rivaroxaban for treating chronic heart failure [ID1462]
Awaiting development [GID-TA10393] Expected publication date: TBC
-
Dulaglutide for treating type 2 diabetes [ID1451]
Awaiting development [GID-TA10439] Expected publication date: TBC
-
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]
Awaiting development [GID-TA10861] Expected publication date: TBC
-
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]
Awaiting development [GID-TA10795] Expected publication date: TBC
-
Bupivacaine–meloxicam for treating postoperative pain [ID2728]
Awaiting development [GID-TA10716] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]
Awaiting development [GID-TA10843] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]
Awaiting development [GID-TA10848] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development [GID-TA10683] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]
Awaiting development [GID-TA10895] Expected publication date: TBC
-
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]
Awaiting development [GID-TA10896] Expected publication date: TBC
-
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Awaiting development [GID-TA10779] Expected publication date: TBC
-
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]
Awaiting development [GID-TA10778] Expected publication date: TBC
-
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Awaiting development [GID-TA10718] Expected publication date: TBC
-
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]
Awaiting development [GID-TA10926] Expected publication date: TBC
-
Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia [ID4042]
Awaiting development [GID-TA10928] Expected publication date: TBC
-
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]
Awaiting development [GID-TA10929] Expected publication date: TBC
-
Pembrolizumab with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID4044]
Awaiting development [GID-TA10930] Expected publication date: TBC
-
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable [ID4045]
Awaiting development [GID-TA10931] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Awaiting development [GID-TA10933] Expected publication date: TBC
-
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Awaiting development [GID-TA10935] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]
Awaiting development [GID-TA10814] Expected publication date: TBC
-
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]
Awaiting development [GID-TA10668] Expected publication date: TBC